Collaborating for Improved Autosomal Dominant Polycystic Kidney Disease (ADPKD) Management

As part of our dedication to providing you leading insights in disease management, Otsuka Pharmaceutical Development & Commercialization, Inc. is pleased to offer Frameworks in Health and Quality: Collaborating for Improved ADPKD Management.

ADPKD is a rare disease that can lead to severe impairment of kidney function and kidney failure.1-3 There were approximately 140,000 diagnosed cases of ADPKD in the United States in 2017.4 It has been estimated that the annual costs associated with end-stage renal disease due to ADPKD are $1.8 billion.5 Identification of patients at risk for rapid progression may provide an opportunity for intervention.6-8

This program is a series of educational resources for healthcare stakeholders, including payers, providers, patients, and their caregivers. It aims to improve understanding of both ADPKD and the need to collaborate together for better management.

Program objectives:

  • Emphasize the importance of understanding ADPKD and its impact
  • Enhance communication among all stakeholders
  • Support the healthcare team with patient and caregiver educational materials
  • Promote ADPKD topics such as management, risk factors for rapid progression, patient engagement, and shared decision making

Payers

Program materials include key issues for payers such as clinical and economic disease burden, identification of at-risk patients, and disease management.

Click here to view these resources.

Healthcare Providers

Program materials include key issues for healthcare providers such as diagnosis, monitoring disease progression, disease management, and potential strategies to collaborate with patients and caregivers to help manage ADPKD.

Click here to view these resources.

Patients and Caregivers

Healthcare professionals may choose to share program materials with patients and their caregivers. Program materials for patients and caregivers focus on education, management, engagement, and communication associated with ADPKD.

Click here to view these resources.

Understanding ADPKD

Evidence demonstrates that earlier detection and management of ADPKD may provide an opportunity for intervention to treat early-onset complications. Our Frameworks in Health and Quality: Collaborating for Improved ADPKD Management program can complement your efforts by providing resources to key stakeholders who are in a position to help improve the care delivered to patients.

Frameworks resources are intended for educational purposes only and are intended for healthcare professionals and/or payer representatives who may choose to share some of these resources with patients or their caregivers. Healthcare professionals should use independent medical judgment when considering Frameworks educational resources. Patients and caregivers should discuss Frameworks materials with a healthcare professional. They are not intended as, nor are they a replacement for, medical advice and treatment from a healthcare professional. Frameworks resources are not intended as reimbursement or legal advice. Users should seek independent, qualified professional advice to ensure their organization is in compliance with the complex legal and regulatory requirements governing healthcare services, and that treatment decisions are made consistent with the applicable standards of care. Frameworks is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.